Delirium, Dementia, Amnestic, Cognitive Disorders  >>  mitoglitazone (MSDC-0160)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
mitoglitazone (MSDC-0160) / Metabolic Solutions
NCT01374438: 3-month Study of MSDC-0160 Effects on Brain Glucose Utilization, Cognition & Safety in Subjects With Alzheimer's Disease

Completed
2
29
US
MSDC-0160, Mitoglitazone, Placebo
Metabolic Solutions Development Company
Alzheimer's Disease
03/13
05/13

Download Options